WILMINGTON, Del., June 11 /PRNewswire/ via NewsEdge Corporation -- Zeneca
Pharmaceuticals has launched a new prostate cancer educational web site for
individuals and medical professionals who are affected by prostate cancer. The
new web site, www.prostateinfo.com, is a vehicle to support the ongoing
commitment of Zeneca to education by providing information to health care
professionals and the public to better prepare for a possible diagnosis of
cancer and ensuing treatment options.
The www.prostateinfo.com links take a viewer through an educational course to
understand prostate cancer, its diagnosis, and available treatment options.
Illustrations help viewers better understand the disease, and there is a
section on coping with prostate cancer which includes a list of cancer support
services. In addition, printed educational material is offered, free of
charge, on the web site.
"Zeneca has a long history of providing quality, objective information
about prostate cancer to men and their families through their physicians,"
said Mark Rickards, Zeneca Senior Product Manager of Oncology Products. "
Making the same information available directly to the public through this web
site is a logical extension of our commitment to service."
According to the American Cancer Society, it is estimated 184,500 new cases of
prostate cancer will be diagnosed, and an estimated 39,200 men will die from
the disease in the United States during 1998. Early diagnosis and medical
information may help save lives. Through education, it is hoped that men
across the world will discuss the disease with their health care professionals
and take advantage of the services available that encourage early detection.
Zeneca is a leading pharmaceutical company in oncology care, with two major
hormonal therapies for the treatment of prostate cancer. CASODEX(R)
(bicalutamide) Tablets is an orally administered antiandrogen used in
combination with a lutenizing hormone-releasing hormone analogue (LHRH-A) for
the treatment of metatstatic D2 (see note) prostate cancer and ZOLADEX(R)
(goserelin acetate implant) is an LHRH-A for the treatment of advanced prostate
cancer. Other web sites from Zeneca provide information on migraine
(www.zomig.com), asthma (www.accolateinfo.com), anesthetics (www.diprivan.com),
and National Breast Cancer Awareness Month (www.nbcam.com).
Zeneca Pharmaceuticals is a business unit of Zeneca Inc. In the United States,
Zeneca Inc. is a $3.4 billion bioscience business with approximately 7,500
employees. Zeneca Inc. is a wholly owned subsidiary of the UK-based Zeneca
Group PLC (NYSE: ZEN), a major $8.6 billion international bioscience business
engaged in the research, development, manufacture, and marketing of ethical
(prescription) pharmaceuticals, agricultural and specialty chemical products,
and the supply of health care services.
For full prescribing information, please call 1-800-456-3669, extension 2231.
Note: The "2" in "D2" is subscript.
SOURCE Zeneca Pharmaceuticals
/CONTACT: Michael Blash of Zeneca Pharmaceuticals, 302-886-5465, or
email, michael.blash@phwilm.zeneca.com/
/Web site: http://www.zomig.com/
/Web site: http://www.accolateinfo.com/
/Web site: http://www.diprivan.com/
/Web site: http://www.nbcam.com/
/Web site: http://www.prostateinfo.com/
(ZEN)
[Copyright 1998, PR Newswire]
Copyright © 1998,
NewsEdge Corporation
No redistribution allowed.
--------------35172DF15178--
